May 13, 2020
Glenmark has successfully developed the API and the formulations for the product through its inhouse R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. The molecule if commercialized, will be marketed under the brand name ‘FabiFlu®’ in India.
– COVID-19 patients from over 10 leading government and private hospitals in India are being
enrolled for the study
– Trial completion and study results expected by July/August 2020
– Glenmark was the first pharmaceutical company in India to be given an approval by the regulator to conduct Phase 3 clinical trials in India on Favipiravir Antiviral tablets for COVID -19 patients.
Commenting on this development, Dr. Monika Ta don, Vice President & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Ltd., said, “Several health and medical experts, both in and outside of Glenmark are eager to see the effect that Favipiravir has on COVID-19 cases. We believe the study results will be significant as there is currently no effective treatment for the virus.” She added, “The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management.”